Context Therapeutics Inc.
CNTX
$0.52
$0.023.26%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 4.70% | 18.56% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 60.19% | -32.31% | |||
| Operating Income | -60.19% | 32.31% | |||
| Income Before Tax | -67.71% | 33.36% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -67.71% | 33.36% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -67.71% | 33.36% | |||
| EBIT | -60.19% | 32.31% | |||
| EBITDA | -60.20% | 32.33% | |||
| EPS Basic | -67.76% | 33.33% | |||
| Normalized Basic EPS | -67.72% | 33.33% | |||
| EPS Diluted | -67.76% | 33.33% | |||
| Normalized Diluted EPS | -67.72% | 33.33% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||